You are here

Dupixent

FDA approves Dupixent for atopic dermatitis in adolescents

FDA approves Dupixent for atopic dermatitis in adolescents

BioCentury

atopic dermatitis

Flag link:

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps

Pharmaforum

clinical trials

Flag link:

7 drugs that raised eyebrows in Q3

7 drugs that raised eyebrows in Q3

Biopharma Dive

Clovis Oncology

Flag link:

Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent

Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent

Endpoints

atopic dermatitis

Flag link:

Sanofi drug Dupixent wins U.S. FDA approval to treat asthma

Sanofi drug Dupixent wins U.S. FDA approval to treat asthma

Yahoo/Reuters

Flag link:

Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII

Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII

Endpoints

Flag link:

Sanofi unveils eczema drug data, as regulators mull label expansion

Sanofi unveils eczema drug data, as regulators mull label expansion

Pharmaforum

atopic dermatitis

Flag link:

Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up

Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up

Endpoints

Flag link:

Sanofi's Dupixent scores NICE recommendation after price cut

Sanofi's Dupixent scores NICE recommendation after price cut

Fierce Pharma

atopic dermatitis

Flag link:

3 Reasons Regeneron Stock Could Start Climbing Again

3 Reasons Regeneron Stock Could Start Climbing Again

Yahoo/Motley Fool

Flag link:

Sanofi blockbuster-to-be skin drug Dupixent fails to win gatekeeper's backing

Sanofi blockbuster-to-be skin drug Dupixent fails to win gatekeeper's backing

Fierce Pharma

Flag link:

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Fierce Pharma

Flag link:

Regeneron-Sanofi food allergy drug succeeds mid-stage study

Regeneron-Sanofi food allergy drug succeeds mid-stage study

Yahoo/Reuters

eosinophilic esophagitis

Flag link:

Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen

Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen

Fierce Pharma

Flag link:

Sanofi indicates dupilumab could be used to treat nasal polyps

Sanofi indicates dupilumab could be used to treat nasal polyps

Yahoo/Reuters

Flag link:

5 Things Regeneron's CEO Said as the Biotech Stock Sank

5 Things Regeneron's CEO Said as the Biotech Stock Sank

Motley Fool

Leonard Schleifer

Flag link:

Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing

Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing

Xconomy

Flag link:

AbbVie preps JAK atopic dermatitis candidate for phase 3

AbbVie preps JAK atopic dermatitis candidate for phase 3

Fierce Biotech

clinical trials

atopic dermatitis

Flag link:

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Fierce Pharma

Flag link:

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Fierce Pharma

Flag link:

Pages